factory Outlets for EUR in Stock CAS 1451-83-8 2-Bromo-3-Methylpropiophenone 2-Bromo-1- (3-methylphenyl) Propan-1-One/236117-38-7/59774-06-0/1009-14-9/705-60-2

Our company puts emphasis on the management, the introduction of talented personnel, and the construction of staff building, trying hard to improve the quality and liability consciousness of staff members. Our company successfully attained IS9001 Certification and European CE Certification of factory Outlets for EUR in Stock CAS 1451-83-8 2-Bromo-3-Methylpropiophenone 2-Bromo-1- (3-methylphenyl) Propan-1-One/236117-38-7/59774-06-0/1009-14-9/705-60-2, We encourage you to make get hold of as we’ve been wanting for companions inside our venture. We are sure you’ll uncover doing company with us not only fruitful but also profitable. We’ve been prepared to provide you with what you require.
Our company puts emphasis on the management, the introduction of talented personnel, and the construction of staff building, trying hard to improve the quality and liability consciousness of staff members. Our company successfully attained IS9001 Certification and European CE Certification of China 1451 83 8 and CAS 1451 83 8, Nowadays our products sell all over the domestic and abroad thanks for the regular and new customers support. We provide high quality product and competitive price, welcome the regular and new customers cooperate with us!

1-Bromo-2-methoxy-3-nitro-benzene is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

Our company puts emphasis on the management, the introduction of talented personnel, and the construction of staff building, trying hard to improve the quality and liability consciousness of staff members. Our company successfully attained IS9001 Certification and European CE Certification of factory Outlets for EUR in Stock CAS 1451-83-8 2-Bromo-3-Methylpropiophenone 2-Bromo-1- (3-methylphenyl) Propan-1-One/236117-38-7/59774-06-0/1009-14-9/705-60-2, We encourage you to make get hold of as we’ve been wanting for companions inside our venture. We are sure you’ll uncover doing company with us not only fruitful but also profitable. We’ve been prepared to provide you with what you require.
factory Outlets for China 1451 83 8 and CAS 1451 83 8, Nowadays our products sell all over the domestic and abroad thanks for the regular and new customers support. We provide high quality product and competitive price, welcome the regular and new customers cooperate with us!